Filtered By:
Source: American Heart Journal
Drug: Aspirin
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 44 results found since Jan 2013.
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial
Publication date: June 2018 Source:American Heart Journal, Volume 200 Author(s): Renato D. Lopes, Amit N. Vora, Danny Liaw, Christopher B. Granger, Harald Darius, Shaun G. Goodman, Roxana Mehran, Stephan Windecker, John H. Alexander Background The optimal antithrombotic strategy for patients with atrial fibrillation (AF) who develop acute coronary syndrome (ACS) and/or the need for percutaneous coronary intervention (PCI) is uncertain. The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic ...
Source: American Heart Journal - April 6, 2018 Category: Cardiology Source Type: research
Rationale and design of the EVOLVE short DAPT study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention
ConclusionThe EVOLVE Short DAPT study will prospectively define the safety of DAPT discontinuation at 3 months in high bleeding risk patients treated with the SYNERGY stent.
Source: American Heart Journal - August 17, 2018 Category: Cardiology Source Type: research
Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease - a meta-analysis of randomized clinical trials
ConclusionsIn patients with atherosclerotic artery disease, the benefit of ticagrelor-based therapies was confined to patients treated for CAD. The drug significantly reduced the risk for all-cause death and MI without excess risk of bleeding in these patients. In consideration of limitations of subgroup analyses, these results need further validation.
Source: American Heart Journal - September 2, 2019 Category: Cardiology Source Type: research
Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease—A meta-analysis of randomized clinical trials
ConclusionsIn patients with atherosclerotic artery disease, the benefit of ticagrelor-based therapies was confined to patients treated for coronary artery disease. The drug significantly reduced the risk for all-cause death and MI without excess risk of bleeding in these patients. In consideration of limitations of subgroup analyses, these results need further validation.
Source: American Heart Journal - November 20, 2019 Category: Cardiology Source Type: research
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial
Conclusions: PEGASUS-TIMI 54 is investigating whether the addition of intensive antiplatelet therapy with ticagrelor to low-dose aspirin reduces major adverse cardiovascular events in high-risk patients with a history of myocardial infarction.
Source: American Heart Journal - January 8, 2014 Category: Cardiology Authors: Marc P. Bonaca, Deepak L. Bhatt, Eugene Braunwald, Marc Cohen, Philippe Gabriel Steg, Robert F. Storey, Peter Held, Eva C. Jensen, Marc S. Sabatine Tags: Trial Design Source Type: research
Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen—Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study
Background: An increasing number of patients undergoing coronary stenting need lifelong anticoagulation and therefore require a triple therapy typically consisting of aspirin, clopidogrel, and a vitamin K antagonist. Triple therapy confers an elevated bleeding risk as compared with dual therapy; however, omission of either antiplatelet or anticoagulation therapy might increase the risk of stent thrombosis or thrombembolic events. Although guidelines recommend a duration of dual antiplatelet therapy of 6 to 12months after drug-eluting stent (DES) implantation, the optimal duration of dual antiplatelet therapy in patients re...
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: K. Anette Fiedler, Robert A. Byrne, Stefanie Schulz, Dirk Sibbing, Julinda Mehilli, Tareq Ibrahim, Michael Maeng, Karl-Ludwig Laugwitz, Adnan Kastrati, Nikolaus Sarafoff Tags: Trial Design Source Type: research
Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare duration of dual antiplatelet therapy after drug-eluting stents
Conclusions Small absolute differences in the risk of ischemic events with longer DAPT would be sufficient to outweigh the known bleeding risks.
Source: American Heart Journal - November 17, 2014 Category: Cardiology Source Type: research
Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents
Conclusions Small absolute differences in the risk of ischemic events with longer DAPT would be sufficient to outweigh the known bleeding risks.
Source: American Heart Journal - December 2, 2014 Category: Cardiology Source Type: research
Long-term outcomes for women vs. men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TRILOGY ACS trial
Conclusions : Long-term ischemic and bleeding outcomes for in medically managed ACS patients were similar for women vs. men, as was treatment-related platelet reactivity. Women had a higher baseline risk profile and, after adjustment, significantly lower risk of the primary composite endpoint and all-cause death through 30 months.
Source: American Heart Journal - June 20, 2015 Category: Cardiology Source Type: research
Long-term outcomes for women versus men with unstable angina/non–ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial
Conclusions Long-term ischemic and bleeding outcomes in medically managed ACS patients were similar for women versus men, as was treatment-related platelet reactivity. Women had a higher baseline risk profile and, after adjustment, significantly lower risk of the primary composite end point and all-cause death through 30 months.
Source: American Heart Journal - September 19, 2015 Category: Cardiology Source Type: research
Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation
Publication date: Available online 1 December 2015 Source:American Heart Journal Author(s): Vincent Johan Nijenhuis, Naoual Bennaghmouch, Mariella Hassell, Jan Baan, Jan Peter van Kuijk, Pierfrancesco Agostoni, Arnoud van ‘t Hof, Peter C. Kievit, Leo Veenstra, Pim van der Harst, Ad F.M. van den Heuvel, Peter den Heijer, Johannes C. Kelder, Vera H. Deneer, Frank van der Kley, Francesco Onorati, Jean Philippe Collet, Francesco Maisano, Azeem Latib, Kurt Huber, Pieter R. Stella, Jurrien M. ten Berg Background Despite improving experience and techniques, ischemic and bleeding complications after Trans...
Source: American Heart Journal - December 1, 2015 Category: Cardiology Source Type: research
Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial
Conclusions In patients who underwent coronary stent implantation, the addition of cilostazol to aspirin therapy was associated with lower rates of cardiovascular and cerebrovascular events at 2 years compared with aspirin monotherapy.
Source: American Heart Journal - January 12, 2016 Category: Cardiology Source Type: research
A Randomized, Parallel Group, Double-Blind Study of Ticagrelor compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation: Rationale and Design of the Ticagrelor in CABG (TiCAB-) Trial
Publication date: Available online 18 June 2016 Source:American Heart Journal Author(s): Antoinette de Waha, Sigrid Sandner, Moritz von Scheidt, Andreas Boening, Katharina Koch-Buettner, Dieter Hammel, Rainer Hambrecht, Bernhard C. Danner, Friedrich A. Schöndube, Gerold Goerlach, Theodor Fischlein, Michael Schmoeckel, Martin Oberhoffer, Rainer Schulz, Thomas Walther, Tibor Ziegelhöffer, Christoph Knosalla, Felix Schönrath, Friedhelm Beyersdorf, Matthias Siepe, Tim Attmann, Martin Misfeld, Friedrich-Wilhelm Mohr, Hans-Hinrich Sievers, Alexander Joost, Leon M. Putman, Günther Laufer, Christia...
Source: American Heart Journal - June 17, 2016 Category: Cardiology Source Type: research
A randomized clinical trial comparing long-term clopidogrel versus aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the HOST-EXAM trial
Conclusions The HOST-EXAM will be the first large-scale randomized controlled study to directly compare the efficacy and safety of long-term antiplatelet monotherapy beyond DAPT after DES implantation. This study will provide clinical evidence to establish optimal regimen for long-term antiplatelet therapy after DES implantation.
Source: American Heart Journal - December 9, 2016 Category: Cardiology Source Type: research
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial
Conclusions The HOST-EXAM will be the first large-scale randomized controlled study to directly compare the efficacy and safety of long-term antiplatelet monotherapy beyond DAPT after DES implantation. This study will provide clinical evidence to establish optimal regimen for long-term antiplatelet therapy after DES implantation.
Source: American Heart Journal - December 20, 2016 Category: Cardiology Source Type: research
